Ingrid is Senior Consultant Regulatory Affairs for Biosimilars at SFL.

Ingrid has more than 30 years of experience in global regulatory affairs and regulatory policy including the lead of a Regulatory Affairs Department for Biopharmaceuticals for 17 years.

Ingrid has achieved numerous pioneering milestones in the history of Biosimilars through a track record of worldwide successful approvals. She had a leading role in the establishment of the regulatory framework for Biosimilars in Europe through her professional work experience and as a member of the Biosimilar Medicines Group of Medicines for Europe, and through the proactive exchange on scientific concepts with regulators.

Through her role as Chairperson of the Biosimilars Committee of the IGBA (International Generic and Biosimilar Medicines Association) working with WHO and national authorities, Ingrid established a strong relationship with authorities worldwide and with WHO.

Ingrid has extensive knowledge of international regulatory guidelines and policy matters, particularly for Biosimilars, and held numerous presentations on Biosimilars at various global conferences.

Ingrid holds a Master of Science degree in Biology from the University of Innsbruck, Austria.